Compliance, Quality of Life, and Cost Effectiveness

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2000 Sep 12

PMID 10981107

Citations 4

Authors

W B Stason

Affiliations

Soon will be listed here.

Citing Articles

Developing a generic, individualised adherence programme for chronic medication users.

Herborg H, Haugbolle L, Sorensen L, Rossing C, Dam P Pharm Pract (Granada). 2014; 6(3):148-57.

PMID: 25177406 PMC: 4148414. DOI: 10.4321/s1886-36552008000300006.

Development of new concepts of non-adherence measurements among users of antihypertensives medicines.

Kjeldsen L, Bjerrum L, Herborg H, Knudsen P, Rossing C, Sondergaard B Int J Clin Pharm. 2011; 33(3):565-72.

PMID: 21526412 DOI: 10.1007/s11096-011-9509-y.

Changes in the continuation of antihypertensive drug use after ALLHAT.

Xie F, Petitti D, Handler J J Clin Hypertens (Greenwich). 2005; 7(11):649-53.

PMID: 16278522 PMC: 8109403. DOI: 10.1111/j.1524-6175.2005.04788.x.

Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies.

Degli Esposti L, Di Martino M, Saragoni S, Sgreccia A, Capone A, Buda S J Clin Hypertens (Greenwich). 2004; 6(2):76-84.

PMID: 14872145 PMC: 8109607. DOI: 10.1111/j.1524-6175.2004.03044.x.

References

Coca A . Actual blood pressure control: are we doing things right?. J Hypertens Suppl. 1998; 16(1):S45-51. View

Edelson J, Weinstein M, Tosteson A, Williams L, Lee T, Goldman L . Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA. 1990; 263(3):407-13. View

Plaisted C, Lin P, Ard J, McClure M, Svetkey L . The effects of dietary patterns on quality of life: a substudy of the Dietary Approaches to Stop Hypertension trial. J Am Diet Assoc. 1999; 99(8 Suppl):S84-9. DOI: 10.1016/s0002-8223(99)00421-6. View

Caro J, Speckman J, Salas M, Raggio G, Jackson J . Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999; 160(1):41-6. PMC: 1229944. View

Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A . Blood-pressure control in the hypertensive population. Lancet. 1997; 349(9050):454-7. DOI: 10.1016/s0140-6736(96)07099-7. View

Rizzo J, Simons W . Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1998; 19(6):1446-57; discussion 1424-5. DOI: 10.1016/s0149-2918(97)80018-5. View

Jackson R . What are the implications for the community of the discrepancy between the theory and practice of BP control?. J Hum Hypertens. 1995; 9 Suppl 2:S25-8. View

Burt V, Whelton P, Roccella E, Brown C, Cutler J, Higgins M . Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25(3):305-13. DOI: 10.1161/01.hyp.25.3.305. View

Hunt S . Quality of life claims in trials of anti-hypertensive therapy. Qual Life Res. 1997; 6(2):185-91. DOI: 10.1023/a:1026498318938. View

10.

Weir M . The rationale for combination versus single-entity therapy in hypertension. Am J Hypertens. 1998; 11(10):163S-169S. DOI: 10.1016/s0895-7061(98)00189-7. View

11.

Applegate W . Quality of life during antihypertensive treatment. Lessons from the Systolic Hypertension in the Elderly Program. Am J Hypertens. 1998; 11(3 Pt 2):57S-61S. DOI: 10.1016/s0895-7061(98)00012-0. View

12.

Applegate W, Pressel S, Wittes J, LUHR J, SHEKELLE R, Camel G . Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994; 154(19):2154-60. View

13.

Testa M, Lenderking W . Interpreting pharmacoeconomic and quality-of-life clinical trial data for use in therapeutics. Pharmacoeconomics. 1992; 2(2):107-17. DOI: 10.2165/00019053-199202020-00004. View